Cristiana Bernini, Autore a NCF International

Still alive and growing

Global report

-

20 June 2014

0

Data, outlook and considerations

Caterina Lazzarini

The 2013 great glaciation went away. Pharmaceutical companies survived the patent cliff of the last two years and are ready to face a 2014 where the market will be stable or slightly growing.

According to IMS Health experts, in 2013, the global pharmaceutical market will grow by 3.1 % and stable or positive trend is foreseen for the next future. A perspective shared even by several other market and financial analysts. According to Moody’s, in 2013 the global pharmaceutical industry will start to produce profits again because only a few top-selling drugs will lose the patent protection, the negative effects of the patent cliff will recede and the quality of research products in late-stage pipeline is high. Several innovative products can drive the sales as oral treatments for Hepatitis C, multiple sclerosis treatments easier to administrate, and oncology drugs more effective on certain types of cancer.

Continue

A new therapeutics market to face a well-known enemy

Global report

Cristiana Bernini

-

20 June 2014

0

A new therapeutics market to face a well-known enemy

Type 2 diabetes is a major concern for a growing segment of population all across the United States and Europe and it is also spreading in the emerging countries. But as a recent Frost & Sullivan report pointed out the demand for innovative therapies and drugs is about to be fulfilled very soon

Roberto Carminati

According to sources, 90 to 95% of the 26 million American citizens struggling with diabetes are indeed suffering from the so-called Type 2 diabetes, once dubbed non-insulin dependent diabetes. Unlike Type 1 diabetes this form of the disease affects people whose body is able to produce insulin but either their pancreas does not make enough insulin or their body is not able to use the insulin well enough.

Continue

Taking care of the Planet Earth

Senza categoria

Cristiana Bernini

-

20 June 2014

0

The Lancet claims in its Manifesto the need for a profound revision of health politics at a level higher than the global one. A new era of Planetary Health should take care of the entire ecosystem in order to be truly sustainable

Giuliana Miglierini

In year 2000 the Millennium Development Goals Declaration of the United Nations set forth a wide list of ambitious endpoints in order to fight against poverty and launch new politics of equitable and sustainable development. The Declaration has been signed by 189 countries; a deep analysis of the current situation and the consequent revision of the goals is scheduled for 2015.

The leading magazine The Lancet is deeply involved in the proposition of a new vision of health politics to be included in the next year’s revision of the Declaration: its Manifesto for a Planetary Health¹ has been published in March 2014 and calls for the involvement of a ‘social movement to support collective public health action’.

Diagnostics is becoming smart(er)

Global report

Cristiana Bernini

-

20 June 2014

0

One of Frost and Sullivan’s most recent Technical insights highlighted how the smart pills market and industry are set to boom in the next few years, driven by a growing demand for more accurate and less invasive analysis technologies that a number of producers are now already striving to meet

Roberto Carminati

The newly-published Innovation in smart pills, a report that Frost & Sullivan included in its Technical insight series, focuses on one of the promised lands and new frontiers that diagnostic and therapeutic applications are about to face in the near future. According to the global market analysis company’s forecasts these solutions are set to rocket in the next five or seven years, reaching their peak, both in terms of value and volume, by 2018-2020. What Frost & Sullivan labels as smart pills is a new generation of capsules and tablets equipped with a number of innovative micro-sensors, imaging and wireless communication chips that can easily be swallowed by any patient. And that, being able to exchange data and images with dedicated hardware and software solutions, can also perform a most accurate monitoring of a patient’s health.

From life’s origins towards artificial life

R&D

Cristiana Bernini

-

20 June 2014

0

From life’s origins towards artificial life

Many important research news in the past few months relates to the investigation of the origin of life, the possibility to generate artificial chromosomes and to create a DNA containing synthetic base pairs. A brief summary of latest discoveries

Giuliana Miglierini

We do all remember about school books describing the origin of life in the ancient oceans and the genetic code made up of only four letters – A, T, G, C – the four DNA’s bases those combinations in triplets encode for the transmission of the hereditary information.

Several studies have been recently published in the scientific literature that may contribute to rewrite these biological paradigms about the origin of life, on one hand, and on the possibility to create artificial DNA or chromosomes, on the other. These last two discoveries are particularly significant as they may open the door to the creation of artificial forms of life, in which DNA and chromosomes might be ‘tailor-made designed’ and synthetized in the lab.

Continue

A wide, complete and versatile range

Packaging

Cristiana Bernini

-

20 June 2014

0

The mode of subministration of spray drugs has been considerably increasing all over the world, thanks to simpleness, hygiene and safety of its application. These performances are the outcome of R&D, that placed ergonomic primary containers made of high quality materials at disposal of the pharmaceutical industry. Inge SpA is well known in Italy and in the foreign countries as one of the main suppliers of primary plastic packaging for the pharmaceutical, veterinary, cosmetic, nutraceutical, diagnostic and household products.

Continue

Quality and customer-oriented creativity

Contract manufacturing

Cristiana Bernini

-

20 June 2014

0

Quality and customer-oriented creativity

High quality standards, high production capacity and flexibility make Mipharm a Centre of Excellence for contract manufacturing and for developing new products and technology platforms

Giovanni Bernuzzi

Mipharm SpA was founded in 1998 by Mr Giuseppe G. Miglio thanks to a management buyout in Novartis Group. The company had worked as pharmaceutical company active in development, manufacturing and marketing of products manufactured at its plant in Milan (former Sandoz Italy facility) since 2009 when Mipharm has focused exclusively on contract manufacturing.

Continue

Three in one to perfection

Packaging

Cristiana Bernini

-

20 June 2014

0

Fifty years ago, rommelag revolutionized plastic packaging technology. A success story of great importance to the pharmaceutical, food and chemical industries. And to the lives of many people

For a change, let’s tell the story in a different way. In January of this year the United Nations Children’s Fund, UNICEF reported that polio had been completely eradicated in India thanks to an unprecedented inoculation campaign. Afghanistan and Nigeria would be next, it announced. Shift of scene: In a vineyard in Germany’s Palatinate region, male grapevine moths are desperately searching for receptive females.

Continue

Disposable bottles for vaginal cream and gel

Packaging

Cristiana Bernini

-

14 April 2014

0

Until today, there were no disposable bottles for vaginal cream and gel; but there are now available, thanks to Inge SpA who, insisting in its expansion and diversification process of its range of primary containers for pharmaceutical use, now fills the gap, supporting the compliance of patients who will have the possibility to apply vaginal cream and gel more easily and more safely.

Continue

Biofarma set up a new Italian probiotic plant

Contract manufacturing

Cristiana Bernini

-

7 April 2014

0

Biofarma set up a new Italian probiotic plant

New Biofarma 4,000 square meters facility to manufacture lactic acid bacteria for food supplements

Giovanni Bernuzzi

Last 23^rd January Biofarma started a new 16 million Euros production site dedicated to lactic ferment supplements. The operation was conducted in partnership with the Danish multinational company Christian Hansen. Biofarma is an Italian company located at Mereto di Tomba (Udine) specialized since 1987 in contract manufacturing of dietary supplements, medical devices, and cosmetics. Danish Christian Hansen is global bioscience company leader in the probiotics for food and pharmaceutical industry.

Continue

Cristiana Bernini

New Biofarma 4,000 square meters facility to manufacture lactic acid bacteria for food supplements

Newsstand